According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled “Administration of benzodiazepine compositions,” says that it “relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.”
The FDA approved Valtoco in January 2020 for the treatment of epilepsy in patients aged 6 years and older. In September 2021, Neurelis announced that it had initiated a Phase 1/2a trial of Valtoco in epilepsy patients aged 2 to 5.
Neurelis President and CEO Craig Chambliss commented, “Our approach to innovation seeks to improve patient outcomes with constant feedback from our patient community. We continue to demonstrate this innovation through the issuance of the ‘414 patent and others under review at the US Patent and Trademark Office. We remain optimistic about our ability to extend the exclusivity of Valtoco beyond 2029.”
Chief Medical Officer Enrique Carrazza added, “This additional patent for Valtoco is a critical milestone that further memorializes our commitment in innovating patient-centric solutions in rare and broader CNS indications. Combined with a robust and growing body of clinical evidence supporting the safety and effectiveness of Valtoco in the treatment of acute episodes of frequent seizure activity, this patent demonstrates our commitment and ability to overcome tough scientific challenges that are barriers to advancing care for patients with epilepsy.”
Read the Neurelis press release.
